Oral salmon calcitonin: Phase I data

In a double-blind Phase I trial in 73 patients, 0.6 and 0.8 mg of oral salmon calcitonin delivered by Emisphere's Eligen technology twice daily significantly reduced CTX-1 and CTX-11 levels vs. placeb...